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Abstract.
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Antisense oligonu-
cleotides that induce skipping of exon 51, 44, 45, or 53 are currently being evaluated in clinical trials. These trials were designed
on the basis of data available in general DMD population.
Objectives: Our objective was to compare the clinical and functional statuses of non-ambulant DMD patients theoretically
treatable by exon 53 skipping and of DMD patients with other mutations.
Methods: We first compared fifteen non-ambulant DMD patients carrying deletions theoretically treatable by exon 53 skipping
(DMD-53) with fifteen closely age-matched DMD patients with mutations not treatable by exon 53 skipping (DMD-all-non-53)
then with fifteen DMD patients carrying deletions not treatable by exon 53 skipping (DMD-del-non-53).
Results: We found that DMD-53 patients had a lower left ventricular ejection fraction, more contractures and they tend to have
weaker grips and pinch strengths than other DMD patients. DMD-53 patients lost ambulation significantly younger than other
DMD patients. This result was confirmed by comparing ages at loss of ambulation in all non-ambulant DMD patients of the
DMD cohort identified in a molecular diagnostic lab.
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Conclusions:These prospective and retrospective data demonstrate that DMD-53 patients have clinically more severe phenotypes
than other DMD patients.
Keywords: Duchenne muscular dystrophy, exon skipping, outcome measures, phenotype-genotype correlation
INTRODUCTION
Among gene and pharmaco-gene therapies, exon
skipping therapy is an emerging approach for treatment
of Duchenne Muscular Dystrophy (DMD) [1–3]. The
aim of exon skipping therapy is to modify processing
of the dystrophin pre-mRNA to allow expression of a
shorter but functional dystrophin protein [4–7]. Exon
skipping naturally occurs in some fibers of patients
resulting in the so-called revertant fibers. Their num-
ber varies with age and type of deletion [8] and may
even result in milder Becker-like phenotype [9]. Anti-
sense oligonucleotides that induce skipping of exon
51, 44, 45, or 53 are currently under evaluation in
clinical trials; some agents have progress to Phase III
evaluation.
There are substantial data that demonstrate a
phenotype-genotype correlation for intellectual func-
tion in DMD patients, with more intellectual disability
in patients with mutations that occur after exon 63
[10–12]. Several studies have reported that motor and
respiratory function and survival of DMD patients
depend on genotype [10, 13, 14]. From analysis of a
large, two-site cohort of 144 patients, Davidson et al.
reported that boys with deletions in the dystrophin
gene were six times more likely to stop walking before
age 10 than were boys with duplications or point or
unknown mutations [15]. Wong et al. showed that
patients with deletions of exons 3–7 presented with
a milder phenotype despite their out of frame deletion
predictive of DMD [16]. Epigenetic or environmen-
tal factors also impact DMD phenotype. High levels
of osteopontin, a secreted multifunction protein, have
recently been reported in a large Italian cohort as
associated with earlier loss of ambulation and more
rapid weakness progression in DMD patients [17, 18].
In a cohort of patients in the United States, LTBP4
haplotype influenced the age of loss of ambulation
[19].
Within the subgroup of patients who might poten-
tially benefit from exon skipping therapy, it is known
that the number of revertant fibers varies greatly regard-
ing the mutated exon. For instance, patients with a
deletion theoretically treatable by exon 44 skipping
present with more revertant fibers than do patients
with a deletion theoretically treatable by exon 51 or
53 skipping [8]. There is no published data on these
patients’ natural history, and therefore the statistical
plans of clinical trials in these specific populations
are designed on the basis of data available from the
general DMD population. Since significant changes in
the patient phenotype and rate of decline may alter
statistical power of these studies, we compared the
clinical and functional parameters for of a cohort of
non-ambulant DMD patients theoretically treatable by
inducing exon 53 with a precisely age-matched over-
all DMD population; the same devices and the same
team evaluated all subjects over the same period of
time. To confirm the data, we retrospectively reviewed
the UMD-DMD-Cochin database for age at loss of
ambulation for patients carrying deletions theoretically
treatable by exon 44, 45, 50, 51, 52, 53, or 55 skipping
and compared data on these patients with data for the
general DMD population.
PATIENTS AND METHODS
Prospective data
Patients were selected from among non-ambulant
patients (i.e., patients not able to walk more than 10
meters without human assistance) included in two
observational natural history studies (Pre-U7 and ULE-
NAP) carried out by the Institute of Myology (Paris)
(Table 1). These studies were approved by the local
ERB and by the French health authority (ANSM)
and were registered with www.clinicaltrials.gov
(NCT01385917 and NCT00993161, respectively)
General design and preliminary data of the multi-
centric study ULENAP have been already reported
[20–22]. In this study, we assessed upper limb strength
and function in 53 non-ambulant DMD patients
(regardless of their mutation) every six months for
one year. All patients were evaluated using a stan-
dardized evaluation. Age at loss of ambulation, steroid
intake, left ventricular ejection fraction (LVEF) and
forced vital capacity (FVC) were obtained from the
available medical files. LVEF and FCV were recorded
only if performed within one year before inclusion
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in the study. All patients underwent clinical exam-
ination and upper limb assessments as previously
described [20]. These assessments included pinch
and handgrip strength measurements by the sensi-
tive devices MyoPinch and MyoGrip, respectively, and
an upper hand assessment using the MoviPlate. Both
arms of each patient were tested. The Motor Function
Measurement (MFM) was also performed. The first
assessment included test-retest evaluation.
In the Pre-U7 study conducted at the Institute of
Myology, we identified 27 patients aged 6 to 20
years old, theoretically treatable by exon 53 skipping.
These patients lived in Belgium, France, Romania, or
Switzerland. One patient with deletion 52 was already
included in an exon 51 skipping trial, two could not be
contacted and one did not wish to participate. Twenty-
three patients (ambulant and non-ambulant) agreed to
take part in the Pre-U7 study (recruitment is ongoing).
Design and assessments were the same as those used
in ULENAP study, and the operating procedures were
similar, except that test-retest assessments were not
conducted in this study. An additional upper limb
assessment using MRI, skin biopsy, and an AAV serol-
ogy assessment were also conducted at the first visit
and then every year. Results are not reported here.
Of the 23 Pre-U7 patients theoretically treatable by
exon 53 skipping (DMD-53), 15 non-ambulant were
compared firstly to age-matched non-ambulant DMD
patients whatever their mutations not treatable by exon
53 skipping (DMD all-non-53), and secondly to age-
matched non-ambulant DMD patients with deletions
not treatable by exon 53 skipping (DMD del-non-53)
(Fig. 1).
Retrospective data
The “laboratoire de biochimie et ge´ne´tique
mole´culaire” (LBGM), Cochin hospital, Paris, is
one of the French molecular diagnosis laborato-
ries dedicated to routine molecular diagnosis of
dystrophinopathies. It also provides data to the
UMD-DMD France database [23]. This database
includes all DMD gene mutations identified in male
subjects as well as symptomatic female carriers
Table 1
Main selection criteria of Pre-U7 and ULENAP studies from which patients were selected
Pre-U7 ULENAP
- DMD theoretically treatable by exon 53 skipping - Neuromuscular disease confirmed by molecular analysis
- Age between 6 and 20 - Age between 5 and 30
- Able to understand rules of assessments - Able to understand rules of assessments
- Ambulant and non-ambulant - Non-ambulant
- Signed informed consent - Signed informed consent
Fig. 1. Flowchart of analyzed patients.
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(www.umd.be/DMD/W DMD/index.html). The clin-
ical section of this database includes 200 fields of
clinical information on each patient, including age at
loss of major motor milestones. For the purpose of the
present work, the age at loss of ambulation of DMD
patients were extracted from the clinical data when
available. These patients will be thereafter referred to
as UMD-DMD-Cochin database patients.
Statistical analysis
DMD all-non-53 and DMD del-non-53 patients
were precisely age-matched to DMD-53 patients on
a patient/patient basis (mean of the difference: 0.2
and 0.3 year respectively, maximal difference 0.9 and
1.1 year respectively). When several patients were
available for matching, the patient with the closest
age was selected. The difference in the distribution
of ages between compared groups was tested by per-
forming a non-parametric Friedman ANOVA test for
paired samples (Fig. 2). There were slight differences
between the two study protocols, especially the test-
retest assessment in the first visit of ULENAP and
the MRI assessment in Pre-U7 study, which that may
induce training or fatigue, respectively. In order to
avoid any possible learning and fatigue effect, clini-
cal, strength and function data from ULENAP study
were those of the first visit of ULENAP, from test
assessment for MyoGrip and MyoPinch and from
retest assessment for MoviPlate. Data from Pre-U7
study were those measured at the second visit. Clin-
ical data, strength and functional data were compared
between groups using a non-parametric Wilcoxon test
for paired samples. Nominal data were compared using
Fig. 2. Distribution of ages of patients included in the analyses.
a Chi squared test with Yates’s correction for continu-
ity if needed. The limit of statistical significance was
set to 0.05.
For retrospective analyses of data from the
UMD-DMD-Cochin database, we first performed the
Kolmogorov-Smirnov test to assess the normal distri-
bution of the age of ambulation in patients carrying
deletions theoretically treatable by exon 44, 45, 50, 51,
52, 53 or 55 skipping. Since the distribution appeared
to be non-normal, we used the non-parametric Kruskal-
Wallis one-way analysis of variance test and a post-hoc
test of Dunn-Bonferroni after verifying the variance’s
homogeneity between groups by Levene’s test. The
age at loss of ambulation between DMD patients car-
rying a deletion treatable by exon 53 skipping and
those carrying all DMD mutations was compared
with the non-parametric independent samples using
Mann-Whitney U Test. Patients with an age at loss
of ambulation older than or equal to 15 years old did
not take part to the statistical analysis.
All analyses were performed using the SPSS 19 sta-
tistical software (SPSS Inc., Chicago, IL). The limit of
statistical significance was set to 0.05.
RESULTS
Selection of patients
The clinical characteristics of patients are detailed
in Table 2. The distribution of ages (13.9 ± 2.9
years vs. 14.0 ± 2.8 years or 14.1 ± 2.8 years in
DMD-53 and DMD-all-non-53 or DMD-del-non-53,
respectively) is displayed in Fig. 2. Even if DMD-
del-non-53 patients appeared to be significantly older
than DMD-53 patients in a Wilcoxon test for paired
samples (p = 0.015), there was no significant dif-
ference between distributions (Friedman ANOVA
p-value = 0.796 and 0.071 for DMD-all-non-53 or
DMD-del-non-53, respectively)
Clinical features
There were no significant difference between DMD-
53 patients and other DMD regarding neither steroid
and cardiac protection (angiotensin-converting-
enzyme inhibitor) treatment nor physiotherapy or
arthrodesis surgery (Table 3). DMD-53 patients
were significantly smaller than non-53 patients
(144 ± 13 cm in DMD-53 vs. 153 ± 12 cm in DMD-
all-non-53 or DMD-del-non-53 patients, p = 0.006 and
p = 0.023 respectively) but there was no significant
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Table 2
Demographic data of patients
Group Age Mutation Height Weight Age at Steroid ACE PT Scoliosis Contractures VEF FVC Brooke
(years) (cm) (Kg) loss of 0: no inhibitor (nb/ 0: no 0: no (% of score
ambulation 1: yes 0: no week) 1: yes 1: yes predicted (#)
(years) (mg per 1: yes 2: arthrosesis value)
day)
53∗∗ 10,3 del48-52 125 30 8 0 0 0 0 0 NA NA 5
53∗∗ 10,6 del52 135 60 6 0 0 1 0 1 36 180 4
53 9,1 del45-52 124 34 8 0 1 4 0 0 64 60 3
53 12,3 del52 137 38 10 1 (20) 0 1 0 0 45 73 2
53∗∗ 12,3 del45-52 153 69 7 0 0 3 1 1 NA 74 5
53 12,5 del49-52 143 53 6 0 1 4 1 1 NA 33 5
53∗∗ 12,7 del45-52 130 27 11 1 (10) 1 5 0 0 45 NA 1
53 14,4 del45-52 154 62 9 0 1 3 2 1 47 30 5
53 14,4 del49-52 147 26 9 0 1 4 1 1 NA 51 5
53 14,6 del45-52 166 40 9 0 1 3 2 1 55 49 5
53 14,9 del52 145 27 7 0 1 3 2 1 50 NA 6
53 15,5 del45-52 153 57 8 0 1 4 1 1 NA 27 5
53 17,6 del50-52 161 28 10 0 1 2 2 1 NA NA 6
53 17,9 del45-52 151 58 10 0 1 7 2 1 60 25 6
53 19,0 del48-52 NA 60 11 0 1 3 1 0 52 NA 3
non53∗a 10,0 c.7392delC 140 30 7 0 1 5 0 0 71 104 4
p.Leu2465∗
non53∗a 12,2 dup8-9 158 55 9 1 (30) NA NA NA NA 61 65 4
non53 a 12,8 c.9459 9462del 156 48 10 0 1 2 1 NA 68 60 4
p.Cys3153∗
non53∗a 14,4 c.7657C>T 155 29 10 0 1 3 2 1 64 41 5
p.Arg2553∗
non53∗a 15,5 c.998C>A 166 40 14 0 1 3 2 1 52 40 5
p.Ser333∗
non53∗b 10,9 del53 134 33 10 1 (NA) 1 2 0 1 64 90 NA
non53∗b 12,1 del3-44 161 39 10 0 0 1 1 1 NA 43 5
non53 b 13,1 del48-50 162 50 11 0 0 5 1 NA 66 68 5
non53∗b 15,7 del42-54 155 29 13 0 1 3 2 1 NA 33 4
non53∗b 15,7 del10-11 150 30 10 0 1 3 2 1 65 30 5
non53 a,b 10,2 del21 135 21 9 0 1 3 0 1 65 56 4
non53 a,b 10,6 del8-13 135 43 10 1 (25) 0 3 1 1 62 77 2
non53 a,b 12,3 del48-54 NA 34 12 1 (15) 0 2 0 0 NA NA 2
non53∗a,b 12,9 del46-49 140 34 10 0 1 3 2 1 55 48 5
non53 a,b 14,2 del5-7 162 47 10 0 1 3 0 1 71 61 5
non53 a,b 14,4 del24-43 165 39 7 0 1 3 2 1 55 47 NA
non53∗a,b 15,2 del8-9 171 52 8 0 0 2 0 1 60 64 5
non53 a,b 17,6 del46-47 165 49 14 0 1 5 2 1 72 65 4
non53 a,b 17,9 del5-7 160 70 13 0 1 4 2 NA 74 61 5
non53 a,b 19,5 del32 160 32 14 0 0 5 2 1 ND 26 5
NA: Not available; ACE: Angiotensin conversion enzyme; PT: Physiotherapy session; VEF: Ventricular ejection fraction; FVC: Forced vital
capacity; ∗: patients previously described in [20]; ∗∗: Romanian patients; a,b: patients used in statistical comparison between 53 and non53-all
mutation (a) or non53-deletion (b).
difference in weight between groups (45 ± 16 kg
in DMD-53 vs. 41 ± 13 kg in DMD-all-non-53
and 40 ± 12 kg in DMD-del-non-53 and, p = 0.532
and p = 0.320 respectively). DMD-53 patients lost
ambulation at a significant younger age than did
the other DMD patients (8.7 ± 1.6 for DMD-53 vs
10.4 ± 2.4, p = 0.031 and 10.7 ± 2.1, p = 0.011 for
DMD-all-non-53 and DMD-del-non-53, respectively).
The left ventricular ejection fraction was significantly
lower in DMD-53 patients and the contracture score
on the dominant side was significantly higher in
DMD-53 patients when compared with DMD patients
carrying deletion not treatable by exon 53 skipping.
No significant differences were observed in the other
clinical features reported (Table 4).
Strength and function
DMD-53 patients presented with lower strength on
both dominant and non-dominant sides as measured
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with MyoGrip and MyoPinch devices in comparison
with both control groups, but those differences did
not reach significance level except for the pinch
Table 3
Treatment analyses
Steroid N P (%) CI
DMD-53 15 13.33 [1.66–40.46]
DMD-all-non-53 15 20.00 [4.33–48.09]
DMD-del-non-53 15 20.00 [4.33–48.09]
ACE Inhibitor N P (%) CI
DMD-53 15 66.67 [38.38–88.18]
DMD-all-non-53 15 60.00 [32.29–83.66]
DMD-del-non-53 14 71.43 [41.90–91.61]
PT N mean (nb/week) SD
DMD-53 15 3.13 1.76
DMD-all-non-53 14 3.29 1.07
DMD-del-non-53 15 3.13 1.19
Arthrodesis N P (%) CI
DMD-53 15 33.33 [11.82–61.62]
DMD-all-non-53 14 50.00 [23.04–76.96]
DMD-del-non-53 15 46.67 [21.27–73.41]
N: number of subjects; P: proportion; CI: confidence interval;
SD: standard deviation; ACE: Angiotensin conversion enzyme; PT:
Physiotherapy session.
strength in comparison with DMD-all-non-53 patients
(0.789 ± 0.440 kg vs 1.236 ± 0.759 kg, p = 0.027 and
0.866 ± 0.486 kg vs 1.408 ± 0.854 kg, p = 0.020 in the
non-dominant and the dominant side respectively)
(Table 5). DMD-53 patients scored lower in the MFM
but the difference did not reach statistical significance.
No difference was observed on the MoviPlate score.
Repartition of strength and function according to dura-
tion since loss of ambulation demonstrated that those
parameters tend to decrease with time spend in a
wheelchair (Fig. 3).
UMD-DMD-Cochin database
Data extracted from the UMD-DMD-Cochin
database (Table 6) indicated that around 6.9% were
carriers of a deletion theoretically treatable by exon
53 skipping. Kruskal-Wallis one-way analysis of vari-
ance was performed to compare ages at loss of
ambulation in patients carrying deletions theoretically
treatable by skipping of exon 44, 45, 50, 51, 52,
53, or 55. This analysis revealed a significant dif-
ference among groups (p = 0.001). DMD-53 patients
Table 4
Clinical features analyses
Group effect Group effect
53 all-non-53 del-non-53 53 vs all-non-53 53 vs del-non-53
N Mean SD Mean SD Mean SD p-value p-value
Duration since loss of ambulation (years) 15 5.2 2.5 3.5 2.1 3.5 2.3 0.047∗ 0.023∗
Contractures-Score-ND 11 5.4 4.5 4.7 3.6 4.9 3.0 0.624 0.624
Contractures-Score-D 11 7.0 4.2 4.7 3.5 5.2 3.1 0.068 0.046∗
Brooke 14 4.4 1.6 4.2 1.1 4.3 1.1 0.718 0.905
Left ventricular ejection fraction (%) 8 50.3 9.1 63.6 7.4 66.7 5.0 0.018∗ 0.028∗
Forced Vital capacity in sitting position 8 56.9 51.4 61.4 21.2 57.1 17.2 0.327 0.483
(% of predictive value)
D: dominant arm; ND: non-dominant arm; N: number of subjects; SD: standard deviation; ∗: significant differences.
Table 5
Force and function data analyses
Group effect Group effect
53 all-non-53 del-non-53 53 vs all-non-53 53 vs del-non-53
N Mean SD Mean SD Mean SD p-value p-value
MyoGrip-ND 15 2.45 1.93 3.67 2.20 3.45 2.23 0.053 0.281
MyoGrip-D 15 2.70 1.89 4.01 2.33 3.58 2.36 0.061 0.281
MyoPinch-ND 15 0.789 0.440 1.236 0.759 1.167 0.808 0.027∗ 0.112
MyoPinch-D 15 0.866 0.486 1.408 0.854 1.351 0.893 0.020∗ 0.078
MoviPlate-ND 14 38 9 38 16 38 14 0.433 0.594
MoviPlate-D 14 43 9 41 15 42 12 0.484 0.826
MFM-D1 (%) 14 1 3 2 3 3 3 0.293 0.307
MFM-D2 (%) 14 43 25 50 27 48 29 0.3 0.551
MFM-D3 (%) 14 71 15 79 16 78 16 0.245 0.278
MFM-Total (%) 14 32 13 37 14 36 15 0.221 0.414
D: dominant arm; ND: non-dominant arm; N: number of subjects; SD: standard deviation; ∗significant differences.
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Fig. 3. Dispersion of data on dominant side for strength (A and B) and motor function (C and D). The full squares represented the DMD-53
patients; the empty squares symbolized DMD-del-non-53 patients; the grey triangle represented DMD patients carrying other mutation (LoA:
Loss of Ambulation).
Table 6
Mean age at loss of ambulation between DMD patients carrying different type of mutation from UMD/DMD-Cochin database
Exon53 Exon51 Exon45 Exon52 DelOut 45–55 AllDMD Exon44 Exon50 Exon55
N patients 92 103 110 49 294 1340 82 54 33
N non-ambulant patients 26 43 37 11 100 442 31 12 8
Mean age at loss of 8.9 ± 1.4 9.3 ± 1.6 9.4 ± 1.8 9.9 ± 1.8 10.0 ± 2.1 10.0 ± 1.9 10.9 ± 1.7 11.2 ± 1.6 11.2 ± 1.8
ambulation ± SD (years) [13]∗ [26]∗ [24]∗ [10]∗ [68]∗ [292]∗ [21]∗ [9]∗ [8]∗
Exon44, 45, 50, 51, 52, 53, 55: patients carrying deletions theoretically treatable by skipping of exon 44, 45, 50, 51, 52, 53 or 55; DelOut45–55:
patients carrying a deletion outside the region limited by exons 45 and 55; AllDMD: all DMD mutations; SD: standard deviation; ∗: number of
subjects for which age at loss of ambulation is available.
lost ambulation significantly earlier than any other
group: 1.2 years earlier than patients with a dele-
tion theoretically treatable by skipping of another
exon such as 44, 45, 50, 51, 52 or 55. (8.9 ± 1.4
years vs. 10.1 ± 1.8 years, p = 0.017), 1.1 years earlier
than patients with a deletion outside the exon 44-55
region (8.9 ± 1.4 years vs. 10.0 ± 2.1 years p = 0.072),
and 1.1 years earlier than patients with any other
kind of mutation (8.9 ± 1.4 years vs. 10.0 ± 1.9 years
p = 0.021). Post hoc test with correction of Bonfer-
roni showed that DMD-53 patients lost ambulation
significantly earlier than DMD patients theoreti-
cally correctible by exon 44 skipping (p = 0.024).
Given the small number of patients in other groups,
differences did not reach statistical significance when
DMD-53 patients were compared with patients car-
rying deletions theoretically treatable by exon 50
or 55 skipping (p = 0.068 and p = 0.100, respec-
tively), who lost ambulation more than two years
later than those theoretically treatable by exon 53
skipping (Fig. 4).
DISCUSSION
Using a prospective methodology and standardized
evaluations, we demonstrated that non-ambulant DMD
patients with a deletion theoretically treatable by exon
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Fig. 4. Box-plot of the age at loss of ambulation of DMD patients
from -UMD-DMD-Cochin database (Exon 44, 45, 50, 51, 52, 53,
55: patients carrying deletions theoretically treatable by skipping of
exon 44, 45, 50, 51, 52, 53 or 55; DelOut45–55: patients carrying
a deletion outside the region limited by exons 45 and 55; AllDMD:
all DMD mutations; rectangles represent the 25th–75th percentile,
the line is the median, ◦: outliers, : faroutliers).
53 skipping tend to have a more severe course than
age-matched controls with DMD patients who could
not be treated by exon 53 skipping whatever are their
mutation. This trend is confirmed even by comparing
only with DMD patients carrying a deletion. The small
number of patients is one of the reason why the level
of significance is not reached. Using a retrospective
methodology on a large population-based database, we
confirmed that patients with a deletion theoretically
treatable by exon 53 skipping lost ambulation more
than one year earlier than other DMD patients.
Selection bias is not a concern with the UMD-
DMD-Cochin database since the inclusion of patients
is exhaustive within the covered territory [23]. Never-
theless, as all patients do not have an estimation of the
amount of dystrophin on muscle biopsy, we choose to
limit the analysis to patients with a DMD phenotype,
this being defined only on clinical ground through the
age of loss of ambulation. Therefore, patients with an
age of loss of ambulation older or equal to fifteen were
not retained for analyses due to a phenotype being more
like a Becker muscular Dystrophy (BMD) which may
introduce a bias in the study. However, the 92 DMD
patients carrying a deletion treatable by exon 53 skip-
ping selected from the UMD-DMD-Cochin database
represented 6.9% of the DMD patients whatever is the
mutation in this database, which is consistent with pre-
viously published data of 7.7% from the largest DMD
database at the Leiden Duchenne Muscular Dystrophy
pages which contains 3.6 time more DMD patients
[24].
In the prospective study, all but four patients from
France, Switzerland, and Romania with a deletion the-
oretically treatable by exon 53 skipping were included,
which rules out a selection bias. DMD care and man-
agement may differ between countries and steroid
treatment is not used widely in all European coun-
tries. Use of steroids is more common in Western
Europe (except France) than Eastern Europe; however,
as we consider only non-ambulant patients, only two
patients were still on steroids including a Romanian.
Inversely, regarding cardiac protection, use of ACE
inhibitor seems less common in Romania as 3 among
the 4 DMD-53 patients without ACE inhibitor were
Romanian. Concerning the number of physiotherapy
sessions, 2 of the 4 Romanian patients had only 1 or 0
session per week, which may introduce a negative
bias in upper limb strength and function evalua-
tion. However, the raw data showed that Romanian
patients were not particularly different from the mean
of the DMD-53 patients. Lastly, even arthrodesis is
not a standard of care in Romania, the scoliosis
status of Romanian patients did not require arthrodesis
surgery.
The control group in the prospective study was first
constituted on the basis of an age-matching strategy.
Assuming that patients carrying a deletion presented
a more severe phenotype than patient with duplica-
tion or point mutation, we constituted a second control
group based on deletion mutation and age-matching
strategy. Both control group presented an age at loss
of ambulation higher but comparable than the general
DMD population of the UMD-DMD Cochin database
(10.4 ± 2.4 and 10.7 ± 2.1 years vs. 10.0 ± 1.9, respec-
tively). The DMD-53 patients tended to be clinically
more severe than other DMD patients. They lost ambu-
lation at a younger age than other DMD patients but,
partly due to the small number of patients, this differ-
ence did not reach statistical significance for several
indicators, such as the MFM, nor the forced vital capac-
ity. Interestingly, DMD-53 patients had a lower LVEF
although mostly under cardiac protection and they
present more contracture on the dominant side than
DMD patients carrying deletions not treatable by exon
53 skipping. This difference did not reach a significant
level when comparing to DMD patients whatever is the
mutation. Brooke score did not suggest any difference
between the groups, which is not surprising given the
poor discrimination power of this 8-point scale. Unex-
pectedly, the specifically designed MoviPlate did not
also suggest any difference between groups. However,
L. Servais et al. / Non-Ambulant DMD Patient’s Phenotype 277
the highly sensitive pinch strength measure devices,
demonstrated distal weakness in DMD-53 patients in
the dominant and non-dominant upper limbs relative
the control group whatever is the mutation. The trend
was maintained comparing with control group carrying
only deletion but the statistical significance was not
reached. This result means that the nature of the muta-
tion could explain a part of the severity in DMD-53
patients. Similar results were obtained with the grip
strength measure device without ever reaching a sta-
tistical significance level. Distal strength through grip
and pinch and motor function of moving fingers and
wrist are cardinal for non-ambulant patients’ auton-
omy (for commanding the wheelchair, writing, using
the computer or phone).
It is generally known that DMD patients are smaller
than the overall population [25]. Interestingly, with an
average of nine centimeters smaller, our results con-
firmed that the DMD-53 patients seem to be even
smaller than the DMD-non-53 controls. Difference in
steroids use when patients were still ambulant may
play a role. This issue should be formally investigated
by getting information on the steroid use during the
ambulant period of patients. The relationship between
height and strength is complex, since strength depends
on size [26]. In addition, steroid treatment is expected
to shorten the stature and increase the strength. At the
time of evaluations, use of steroids in DMD-53 and
control-groups patients was stopped for most of them,
so we could expect that steroid treatment previously
received influence strength by reducing the height of
DMD-53 patients. To our knowledge, no data regard-
ing variations of clinical course nor muscle strength
or function has been published in the specific popula-
tions of patients treatable by exon skipping. However,
our findings are in line with a current UK based study
on North Star data [27], and of a Dutch cohort [28],
which demonstrated a less severe phenotype in patients
theoretically skippable by exon 44 skipping. A recent
Italian prospective study in ambulant patients failed
to demonstrate any significant difference in 6 minutes
walking test drop across the different groups of patients
eligible for exon skipping, except for patients treatable
by exon skipping 44 who present a slower drop [29].
The more than one year difference in age at loss of
ambulation between DMD-53 and DMD-non-53 con-
trols observed in the prospective and retrospective data
implies a faster rate of decline during the ambulation
period in DMD-53 patients which must be taken into
account in the design of the clinical trials in these
populations. This difference would affect not only the
statistical powering of the studies but also the selection
of control groups for non-placebo-controlled studies.
The number of revertant fibers is known to be differ-
ent between the various sub-groups of patients with
genotypes treatable by exon skipping. For instance,
patients eligible for exon skipping 44 present more
revertant fibers than patients eligible for exon 51 skip-
ping [8]. This is a possible explanation for differences
in the age at loss of ambulation in these patients.
Indeed, the classification between groups that can be
established from the UMD-DMD-database regarding
DMD-53 and DMD-51 patients for which the age at
loss of ambulation is lower than DMD-44 patients
matches the data available on revertant fiber numbers.
This classification of subgroups is also consistent with
the North Star data [27]. It is known that specific sub-
groups of DMD patients, such as those with deletions
of exons 2–7, may present a milder phenotype, but it
is unlikely that the inclusion of these subgroups in the
general DMD population can account for the difference
between DMD-53 and DMD-non-53 patients.
Mutations that are theoretically treatable by exon 53
skipping include different genotypes, such as del 52,
del 50–52, and del 49–52. Probably any of the existing
series include enough patients to determinate whether
they present a similar phenotype. In the present dataset,
no obvious differences appear between sub-groups, but
although we had a very large cohort of patients theo-
retically treatable by inducing exon 53 skipping, this
study was not statistically powered to assess this ques-
tion. Pooling the data from the different nation-wide
databases is required to address this question. Larger
datasets would also be required to assess whether the
more severe phenotype of DMD-53 patients could
be related to a weaker respond to steroids, which is
suggested by the higher percentage of DMD-53 than
DMD-non-53 patients in our study who were treated
with steroids at the time of the study, despite a more
severe phenotype.
Studying non-ambulant patients allowed a retro-
spective overview of the natural history of the disease.
It is commonly assumed that in DMD patients the
age of occurrence of clinically meaningful endpoints
is correlated with lifespan [30]. Replication of these
findings in other large databases or in well conducted
prospective studies and further mechanistic studies
are required to better understand the specificity of the
phenotype of 53-DMD patients. We believe that the
present data are important and clinically meaningful
in the context of the ongoing exon skipping trials. In
conclusion, our investigation on the characterization
of the phenotype of non-ambulant DMD patients
theoretically treatable by inducing exon 53 skipping
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showed that this highly specific subgroup of patients
is significantly weaker than the general DMD popu-
lation. This aspect should be taken into account in the
design and statistical plan of future therapeutic clinical
trials.
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